1. Home
  2. MMTX vs CGTX Comparison

MMTX vs CGTX Comparison

Compare MMTX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMTX

Miluna Acquisition Corp Class A Ordinary Share

N/A

Current Price

$10.18

Market Cap

89.8M

Sector

Finance

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$1.03

Market Cap

79.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MMTX
CGTX
Founded
2025
2007
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.8M
79.6M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
MMTX
CGTX
Price
$10.18
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
16.5K
519.6K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.89
$0.55
52 Week High
$10.21
$2.67

Technical Indicators

Market Signals
Indicator
MMTX
CGTX
Relative Strength Index (RSI) 51.70 54.48
Support Level $10.09 $1.02
Resistance Level N/A $1.18
Average True Range (ATR) 0.02 0.05
MACD 0.00 0.01
Stochastic Oscillator 33.33 73.51

Price Performance

Historical Comparison
MMTX
CGTX

About MMTX Miluna Acquisition Corp Class A Ordinary Share

Miluna Acquisition Corp is a blank check company.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: